Curietherapies 10th annual meeting: Moving Brachytherapy Forward

At the end of this presentation, the participant will be able to:

• Discuss the EMBRACE initiative
• Discuss their contouring proposal and the OAR constraints
• Understand  the necessity for imaging in cervix brachytherapy

Evaluation 

At the end of this presentation, the participant will be able to:

• Understand the indications for interstitial or endocavitary brachytherapy
• Discuss the use of brachytherapy in early-stage endometrial cancer 
• Understand the treatment of inoperable patients

Evaluation

At the end of this presentation, the participant will be able to:

• Explain the need for live imaging during the interstitial implantation
• Explain the usefulness of a transrectal ultrasound in this setting
• Determine which endorectal probe to use

Evaluation 

At the end of this presentation, the participant will be able to:

• Debate the benefit of 3D imaging in vaginal cuff brachytherapy
• Determine which type of 3D imaging is best suited in this setting
• Understand concepts of 3D imaging and contouring in brachytherapy for recurrent uterine cancers

Evaluation

Evaluation 

At the end of this presentation, the participant will be able to:

• Explain how to commission applicators with advanced dose calculation algorithms.
• Discuss clinical advantages of advanced dose calculation algorithms. 
• Evaluate differences in dosimetry between algorithms.

Evaluation 

At the end of this presentation, the participant will be able to:

• Explain the difference between a model-based dose calculation and TG-43 calculation
• Discuss wich anatomical sites will most benefit from higher dose calculation accuracy
• Discuss which new clinical approaches (ex: shielded applicators) model-based dose calculation will favor clinical implementation 

Evaluation

At the end of this presentation, the participant will be able to: 

• Describe the tools used to obtain in vivo dosimetry.
• Discuss the advantages and limitations of in vivo dosimetry.
• Recognize when in vivo dosimetry will bring a plus to the treatment (ex. daily dose tracking and possible adaptive process).

Evaluation 

• Describe the tools needed for deep learning.
• Discuss the areas where deep learning methods can be applied in the brachytherapy process.
• Discuss effective strategies for introducing automatization in the brachytherapy process.

Evaluation 

13:10: Fabian Svahn

Intesity-modulated vaginal cuff brachytherapy

13:20: Yujing Zou

Predictive modeling of post-radiation therapy recurrence for gynecological cancer patients using clinical and histopathology imaging features: a proof-of-concept

13:30: Maude Robitaille

Focal treatment of prostate cancer with Yb-169 high dose rate intensity modulated brachytherapy

At the end of this presentation, the participant will be able to:

• Analyse the needle placement for an optimal dosimetry

Evaluation 

At the end of this activity, the participant will be able to:

• Discriminate between the different available applicators
• Discuss dosimetry
• Analyze the feasibility of the implant

Evaluation 

• How to use the different applicators
• 3D printers
• Discuss dosimetry
• What to be aware of
• Evaluate

Evaluation

At the end of this presentation, the participant will be able to:

• Discuss the imaging for the implant and the dosimetry
• Discuss the benefit of a DIL boost
• Analyse the IPSA dosimetry and its weaknesses

Evaluation 

At the end of this activity, the participant will be able to:

• Differentiate the  different brachytherapy techniques that can be used in skin cancer
• Determine which technique is best suited for a given patient
• Discuss the results and toxicity of skin brachytherapy

Evaluation 

At the end of this activity, the participant will be able to:

• Discuss the use of 3D printers in plesiotherapy
• Debate the technical difficulties and limitations of this technique
• Debate the limitations of the available commercial softwares

Evaluation 

At the end of this activity, the participant will be able to:

• Determine brachytherapy inmdications for these tumor sites
• Explain the implantation techniques

Evaluation

At the end of this activity, the participant will be able to:

• Determine brachytherapy indications for these tumor sites
• Explain the implantation techniques
• Discuss the results and toxicities

Evaluation 

At the end of this activity, the participant will be able to:

• Determine brachytherapy indications for these tumor sites
• Explain the implantation techniques
• Discuss the results and toxicities

Evaluation 

At the end of this activity, the participant will be able to:

• Enumerate the indications for image-guided brachytherapy in non-traditional sites
• Debate the need of live imaging during implantation for certain sites

Evaluation

At the end of this activity, the participant will be able to:

• Explain how to obtain synthetic imaging from MRI
• Explain the role of AL and deep-learning during this process
• Explain the benefits of this technique in the clinical setting

Evaluation 

At the end of this activity, the participant will be able to:

• Explain the difficulties posed for needle reconstruction with MRI only
• Determine which sequence would be  best suited for reconstruction

Evaluation

At the end of this activity, the participant will be able to:

• Evaluate the available literature
• Debate the  results and toxicities of this combination treatment
• Explain the rationale behind the summation of HDR and EBRT dose-fractionations

Evaluation 

At the end of this activity, the participant will be able to:

• Analyze the difference in precision between both techniques
• Compare the cost of  each technique
• Compare  results between both techniques

Evaluation 

At the end of this activity, the participant will be able to:

• Analyze the available  literature
• Analyze the feasibility of this workflow
• Debate the constraints of  this technique

Evaluation 

At the end of this activity, the participant will be able to:

• Explain the controversy behind the use of PSA as a surrogate for survival  in current studies
• Analyze and compare the different PSA failure definitions
• Debate the need for another marker of survival in the curative setting

Evaluation

At the end of this activity, the participant will be able to:

• Describe the available tests
• Determine the indications of these tests
• Discuss the usefulness of genomics in the curative setting

Evaluation 

At the end of this activity, the participant will be able to:

• Analyze the available literature
• Discuss the  possible indications  and results
• Determine  if ARAT should become  a standard in the curative setting

Evaluation 

At the end of this activity, the participant will be able to:

• Define focal  therapy  in prostate cancer
• Determine the indications for focal prostate brachytherapy
• Explain the implantation techniques and need of imaging
• Discuss the results and toxicity

Evaluation